Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anand Lothe

Internal Medicine Glen Allen, VA Medical Doctor

NPI 1851343180 CMS profile 355982

4900 Cox Rd, Suite 150, Glen Allen, VA 23060

Open in the dashboard

General payments

$8,581

573 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anand Lothe of Glen Allen, VA is reported in the CMS Open Payments database as having received $8,581 across 573 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,453 98
2024 General $1,320 84
2023 General $536 43
2022 General $1,347 80
2021 General $1,521 97
2020 General $1,083 80
2019 General $1,322 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anand Lothe
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Anand Lothe were reported at $1,453. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Anand Lothe Internal Medicine median Middle half National median
2019 $1,322 $159 $48–$570 $163
2020 $1,083 $119 $33–$402 $114
2021 $1,521 $135 $37–$521 $132
2022 $1,347 $141 $42–$496 $149
2023 $536 $149 $45–$519 $160
2024 $1,320 $154 $47–$537 $164
2025 $1,453 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,347 118 payments
  2. Pfizer Inc. $922 56 payments
  3. Amgen Inc. $808 53 payments
  4. Novo Nordisk Inc $713 49 payments
  5. GlaxoSmithKline, LLC. $432 32 payments
  6. AstraZeneca Pharmaceuticals LP $420 29 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $395 21 payments
  8. Janssen Pharmaceuticals, Inc $350 18 payments
  9. Lilly USA, LLC $309 18 payments
  10. Abbott Laboratories $221 14 payments
  11. Other $2,664 165 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,544 570 payments
  2. Education $20 2 payments
  3. Entertainment $17 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY $837 74 payments
  2. QULIPTA $586 59 payments
  3. Prolia $423 26 payments
  4. Repatha $401 28 payments
  5. NURTEC ODT $399 22 payments
  6. EVENITY $393 24 payments
  7. Ozempic $391 26 payments
  8. XARELTO $350 18 payments
  9. JARDIANCE $348 18 payments
  10. RYBELSUS $290 19 payments
  11. Other $7,608 501 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 101 drugs

Part D claims

5,634

Median for Internal Medicine: 777

Drug cost

$415,649

Median for Internal Medicine: $73,373

Branded share of claims

18.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 68 $106,955
Xarelto Rivaroxaban Brand 55 $73,093
Eliquis Apixaban Brand 63 $66,791
Rybelsus Semaglutide Brand 35 $46,442
Januvia Sitagliptin Phosphate Brand 15 $23,056
Farxiga Dapagliflozin Propanediol Brand 12 $19,771
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 36 $6,761
Atorvastatin Calcium Generic 627 $5,350
Wixela Inhub Fluticasone Propion/Salmeterol Brand 26 $4,095
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 23 $4,076

The 10 drugs with the highest cost, of 101 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$190,959

Of which drugs: $65,398

Medicare patients

454

Average age 75

Services billed

4,914

214 women, 240 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Arthritis 38%
Ischemic heart disease 20%
Diabetes 18%
Osteoporosis 16%
Cancer 15%
Atrial fibrillation 12%
Chronic kidney disease 9%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 25 2,580 $52,649
Vaccine for influenza for injection into muscle 90662 Office 63 63 $5,073
Pcv20 vaccine im 90677 Office 15 15 $4,326
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 20 20 $3,168

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Heplisav-B
  • Dynavax Technologies Corporation $112
$112 — —
QULIPTA
  • AbbVie, Inc. $105
$105 — —
UBRELVY
  • AbbVie, Inc. $80
$80 — —
ZEPBOUND
  • Lilly USA, LLC $67
$67 — —
Wegovy
  • Novo Nordisk Inc $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

573 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record